GlassScriptPhysician profile
Christopher J Kottenstette
NPI 1023099348
$5,819.34
in general payments reported to CMS, 2019-2025
34 companies · $1,673 in 2025
The $1,673 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,287 · 2022: $1,025 · 2023: $966 · 2024: $869 · 2025: $1,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,474 · Travel and Lodging: $33.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,473.57 |
| Travel and Lodging | $33.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $899.00 | 2021-2023 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $666.51 | 2021-2025 | Relistor |
| Saluda Medical Americas, INC. | $650.64 | 2025 | Evoke |
| Abbvie INC. | $378.44 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $358.61 | 2022 | |
| Pfizer INC. | $294.61 | 2021-2025 | |
| Abbott Laboratories | $254.16 | 2021-2024 | Eterna |
| Scilex Pharmaceuticals INC. | $248.19 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $198.86 | 2023-2025 | Belbuca |
| Spr Therapeutics, INC | $198.43 | 2022-2025 | Sprint Pns System |
| Biohaven Pharmaceuticals, INC. | $179.77 | 2021 | |
| Boston Scientific Corporation | $159.18 | 2021 | |
| Radius Health, INC. | $144.20 | 2021-2023 | Tymlos |
| Vertex Pharmaceuticals Incorporated | $144.07 | 2024-2025 | |
| Curonix LLC | $140.32 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $129.12 | 2021-2024 | Emgality, Reyvow |
| Medtronic, INC. | $86.10 | 2021-2023 | Plasmablade(Tm) |
| Nevro Corp. | $81.24 | 2022-2023 | Senza |
| Nuvasive, INC. | $75.97 | 2021 | |
| Globus Medical, INC. | $67.66 | 2025 | Senza |
| Axsome Therapeutics, INC. | $63.07 | 2025 | Symbravo |
| Nalu Medical, INC. | $62.81 | 2021-2022 | |
| Redhill Biopharma INC. | $61.86 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $41.70 | 2023 | Quviviq |
| Alvogen INC | $39.87 | 2021-2023 | Teriparatide |
| Davol INC. | $33.30 | 2022 | |
| Eisai INC. | $26.32 | 2021 | |
| Stryker Corporation | $24.61 | 2022 | |
| Depuy Synthes Sales INC. | $23.96 | 2025 | Orthovisc, Monovisc |
| Alfasigma USA, INC. | $19.05 | 2021 | |
| Biodelivery Sciences International, INC. | $18.50 | 2021 | |
| Integra Lifesciences Corporation | $18.17 | 2021 | |
| Mml US, INC. | $17.88 | 2023 | Reactiv8 |
| Augmedics INC. | $13.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kottenstette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.